• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4596627)   Today's Articles (4369)   Subscriber (49344)
Number Citation Analysis
26
Chen X, He J, Shen H, Xi Y, Chen B, He X, Gao J, Yu H, Shen W. 97P Aumolertinib as adjuvant therapy in postoperative EGFR-mutated stage I–III non-small cell lung cancer with high-risk pathological factors. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00352-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2023]
27
Kilickap S, Özgüroğlu M, Sezer A, Gumus M, Bondarenko I, Gogishvili M, Türk H, Cicin I, Bentsion D, Gladkov O, Clingan P, Sriuranpong V, He X, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P. 10MO EMPOWER-Lung 1: Cemiplimab (CEMI) monotherapy as first-line (1L) treatment of patients (pts) with brain metastases from advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% — 3-year update. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00264-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2023]
28
Kalinka E, Bondarenko I, Gogishvili M, Melkadze T, Baramidze A, Sezer A, Makharadze T, Kilickap S, Gumus M, Penkov K, Giorgadze D, Özgüroğlu M, He X, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P. 114M0 First-line cemiplimab for locally advanced non-small cell lung cancer: Updated subgroup analyses from EMPOWER-Lung 1 and EMPOWER-Lung 3. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00369-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2023]
29
Zhang H, Jiang J, He X, Zhou Q. Circ_0002111/miR-134-5p/FSTL1 signal axis regulates tumor progression and glycolytic metabolism in papillary thyroid carcinoma cells. J Endocrinol Invest 2023;46:713-725. [PMID: 36227499 DOI: 10.1007/s40618-022-01921-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/30/2022] [Accepted: 09/11/2022] [Indexed: 10/17/2022]
30
Gu Y, Xu W, Liu Y, An X, Li J, Cong L, Zhu L, He X, Wang H, Jiang Y. The feasibility of a novel computer-aided classification system for the characterisation and diagnosis of breast masses on ultrasound: a single-centre preliminary test study. Clin Radiol 2023:S0009-9260(23)00130-7. [PMID: 37069025 DOI: 10.1016/j.crad.2023.03.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2022] [Revised: 03/07/2023] [Accepted: 03/15/2023] [Indexed: 04/19/2023]
31
Garassino M, Kilickap S, Özgüroğlu M, Sezer A, Gumus M, Bondarenko I, Gogishvili M, Nechaeva M, Schenker M, Cicin I, Fuang H, Kulyaba Y, Dvorkin M, Zyuhal K, Scheusan RI, He X, Kaul M, Okoye E, Li Y, Li S, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P. OA01.05 Three-year Outcomes per PD-L1 Status and Continued Cemiplimab Beyond Progression + Chemotherapy: EMPOWER-Lung 1. J Thorac Oncol 2023. [DOI: 10.1016/j.jtho.2022.09.122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
32
Yu SY, He X, Tian ZL, Li KX, Chen H, Wang HM, Shi ZS, Zhu S, Cui ZC. Effect of Collagen-Reactive Functional Monomer on Etch-and-Rinse Adhesives. J Dent Res 2023;102:287-294. [PMID: 36474440 DOI: 10.1177/00220345221134278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]  Open
33
Barut I, He X, Sener E, Sämfors S, Ewing AG, Fletcher J. Correlative Cellular Mass Spectrometry Imaging and Amperometry Show Dose Dependent Changes in Lipid Composition and Exocytosis. Angew Chem Int Ed Engl 2023. [DOI: 10.1002/ange.202217993] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/10/2023]
34
Barut I, He X, Sener E, Sämfors S, Ewing AG, Fletcher JS. Correlative Cellular Mass Spectrometry Imaging and Amperometry Show Dose Dependent Changes in Lipid Composition and Exocytosis. Angew Chem Int Ed Engl 2023;62:e202217993. [PMID: 36749546 DOI: 10.1002/anie.202217993] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2022] [Revised: 01/27/2023] [Accepted: 02/07/2023] [Indexed: 02/08/2023]
35
Zhao J, Ip DKM, Leung JYY, Vackova D, He X, Schooling CM. Effect of berberine on cardiovascular disease risk factors: abridged secondary publication. Hong Kong Med J 2023;29 Suppl 2:39-41. [PMID: 36951006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/24/2023]  Open
36
Wang B, Deng Y, Xu Q, Gao J, Shen H, He X, Ding Q, Wang F, Guo H. Exploration of 68Ga-labelled prostate-specific membrane antigen-11 PET/CT parameters for identifying PBRM1 status in primary clear cell renal cell carcinoma. Clin Radiol 2023;78:e417-e424. [PMID: 36805287 DOI: 10.1016/j.crad.2023.01.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2022] [Revised: 12/26/2022] [Accepted: 01/10/2023] [Indexed: 02/04/2023]
37
Xiong T, Li C, He X, Xie B, Zong J, Jiang Y, Ma W, Wu F, Fei J, Yu P, Mao L. Neuromorphic functions with a polyelectrolyte-confined fluidic memristor. Science 2023;379:156-161. [PMID: 36634194 DOI: 10.1126/science.adc9150] [Citation(s) in RCA: 52] [Impact Index Per Article: 52.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
38
Chen M, Chen YM, Lu Y, He X, Peng H, Zhang HY. [Cryptic COL1A1-PDGFB fusion in dermatofibrosarcoma protuberans: a clinicopathological and genetic analysis]. ZHONGHUA BING LI XUE ZA ZHI = CHINESE JOURNAL OF PATHOLOGY 2023;52:13-18. [PMID: 36617900 DOI: 10.3760/cma.j.cn112151-20221006-00832] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
39
He X, Zheng Y, Wang J. Neoadjuvant Chemotherapy Efficacy and Safety in Borderline Resectable Pancreatic Cancer. Indian J Pharm Sci 2023. [DOI: 10.36468/pharmaceutical-sciences.spl.613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/19/2023]  Open
40
L. Zuo, Zhou S, Liu P, Yang S, Yang J, He X, Gui L, Li R, Yang Y. 106P Zanubrutinib in combination with tislelizumab in patients with refractory diffuse large B cell lymphoma (DLBCL): A phase II study. IMMUNO-ONCOLOGY AND TECHNOLOGY 2022. [DOI: 10.1016/j.iotech.2022.100210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
41
Zhou S, Zuo L, Yang S, He X, Yang J, Gui L, Li R, Yang Y. 99P Sintilimab plus nab-paclitaxel in platinum-refractory head and neck squamous cell carcinoma: A phase II trial. IMMUNO-ONCOLOGY AND TECHNOLOGY 2022. [DOI: 10.1016/j.iotech.2022.100203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
42
Ho G, Sezer A, Kilickap S, Gumus M, Bondarenko I, Ozguroglu M, Gogishvili M, He X, Gullo G, Rietschel P, Quek R. 334P Patient-reported outcomes with cemiplimab versus chemotherapy in advanced non-small cell lung cancer (aNSCLC): Geographic region subgroups in EMPOWER-Lung 1. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.372] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022]  Open
43
Zheng X, Zhang L, Liu X, Qu B, Zhong Q, Qian L, Yang Y, Xiaorong H, Qiao X, Wang H, Zhu Y, Cao J, Wu J, Wu T, Zhu S, Shi M, Zhang H, Zhang X, Su H, Song Y, Zhu J, Zhang Y, Huang H, Wang Y, Chen F, Yin L, He X, He X, Qi S, Li Y. Pattern and Prognosis of Distant Metastases in Patients with Early-Stage Extranodal Nasal-Type NK/T-Cell Lymphoma. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
44
Hatamie A, He X, Zhang XW, Oomen PE, Ewing AG. Advances in nano/microscale electrochemical sensors and biosensors for analysis of single vesicles, a key nanoscale organelle in cellular communication. Biosens Bioelectron 2022;220:114899. [DOI: 10.1016/j.bios.2022.114899] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2022] [Revised: 11/03/2022] [Accepted: 11/07/2022] [Indexed: 11/11/2022]
45
Gui L, He X, Yang J, Liu P, Qin Y, Shi YK. 230MO Pembrolizumab plus anlotinib as first-line treatment in patients of CPS≥1 with recurrent or metastatic head and neck squamous-cell carcinoma: A prospective phase II study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022]  Open
46
Xin L, Zhang L, Qu B, Zhong Q, Qian L, Yang Y, Xiaorong H, Qiao X, Wang H, Zhu Y, Wu J, Wu T, Zhu S, Shi M, Zhang H, Zhang X, Su H, Song Y, Zhu J, Zhang Y, Huang H, Wang Y, Chen F, Yin L, He X, Cai S, Qi S, Li Y. Evidence of Cure for Extranodal Nasal-Type NK/T-Cell Lymphoma with Modern Treatment. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
47
Gui L, He X, Yang J, Liu P, Yan Q, Shi YK. 683P Pembrolizumab plus nabpaclitaxe and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma: A prospective phase II study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.807] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]  Open
48
Kilickap S, Sezer A, Gümüş M, Bondarenko I, Özgüroğlu M, Gogishvili M, He X, Gullo G, Rietschel P, Quek R. P1.15-12 Patient-reported Outcomes of Cemiplimab versus Chemotherapy in Advanced NSCLC: PD-L1 Level Subgroups in EMPOWER-Lung 1. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
49
Lin Y, Yang H, Shi F, Yang A, Han X, Liu B, Li Z, Ji Q, Tang L, Deng Z, Ding Y, Fu W, Xie X, Li L, He X, Lv Z, Wu L, Liu L. 1644O Donafenib in locally advanced/metastatic, radioactive iodine-refractory, differentiated thyroid cancer: A randomized, double-blind, placebo-controlled, multi-center phase III clinical trial (DIRECTION). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1724] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]  Open
50
Xiao W, Chen L, Xuan T, He X, Yu H, Zhu X, Luo N, Li M, Qi Y, Sun T, Qi C. 1769P KDM6A mutation act as a potential immunotherapy biomarker in urothelial carcinoma. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1847] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]  Open
PrevPage 2 of 43 123454243Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA